Trial · NCT01613118
Adverse events705
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 705
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Infections and infestations | RE-021 (Sparsentan) 200 mg - Double-Blind Period | 0 | 13 | 0 |
| other | COVID-19 | Infections and infestations | RE-021 (Sparsentan) 400 mg - Double-Blind Period | 0 | 26 | 0 |
| other | COVID-19 | Infections and infestations | RE-021 (Sparsentan) 800 mg - Double-Blind Period | 0 | 34 | 0 |
| other | COVID-19 | Infections and infestations | Irbesartan 300 mg - Double-Blind Period | 0 | 36 | 0 |
| other | COVID-19 | Infections and infestations | All Sparsentan (Double-Blind and Open-Label Extension) | 17 | 108 | 19 |
| other | Upper respiratory tract infection | Infections and infestations | RE-021 (Sparsentan) 200 mg - Double-Blind Period | 0 | 13 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | RE-021 (Sparsentan) 400 mg - Double-Blind Period | 0 | 26 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | RE-021 (Sparsentan) 800 mg - Double-Blind Period | 2 | 34 | 3 |
| other | Upper respiratory tract infection | Infections and infestations | Irbesartan 300 mg - Double-Blind Period | 2 | 36 | 2 |
| other | Upper respiratory tract infection | Infections and infestations | All Sparsentan (Double-Blind and Open-Label Extension) | 17 | 108 | 43 |
| other | Nasopharyngitis | Infections and infestations | RE-021 (Sparsentan) 200 mg - Double-Blind Period | 0 | 13 | 0 |
| other | Nasopharyngitis | Infections and infestations | RE-021 (Sparsentan) 400 mg - Double-Blind Period | 0 | 26 | 0 |
| other | Nasopharyngitis | Infections and infestations | RE-021 (Sparsentan) 800 mg - Double-Blind Period | 1 | 34 | 1 |
| other | Nasopharyngitis | Infections and infestations | Irbesartan 300 mg - Double-Blind Period | 0 | 36 | 0 |
| other | Nasopharyngitis | Infections and infestations | All Sparsentan (Double-Blind and Open-Label Extension) | 13 | 108 | 23 |
| other | Urinary tract infection | Infections and infestations | RE-021 (Sparsentan) 200 mg - Double-Blind Period | 0 | 13 | 0 |
| other | Urinary tract infection | Infections and infestations | RE-021 (Sparsentan) 400 mg - Double-Blind Period | 1 | 26 | 1 |
| other | Urinary tract infection | Infections and infestations | RE-021 (Sparsentan) 800 mg - Double-Blind Period | 0 | 34 | 0 |
| other | Urinary tract infection | Infections and infestations | Irbesartan 300 mg - Double-Blind Period | 0 | 36 | 0 |
| other | Urinary tract infection | Infections and infestations | All Sparsentan (Double-Blind and Open-Label Extension) | 11 | 108 | 22 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01613118/events